Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex
Qi Hao(ISCO International (United States)), Michael E. Kort(AbbVie (United States)), Mark E. Fitzgerald(C4 Therapeutics (United States)), Amirhossein Mafi(Enzo Life Sciences (United States)), Christopher G. Nasveschuk(C4 Therapeutics (United States)), Marcia N. Paddock(California State University, San Marcos), Kelly L. Klinge(AbbVie (United States)), James A. Henderson(C4 Therapeutics (United States)), Matthew Bratkowski, Gesine K. Veits(C4 Therapeutics (United States)), Vincent S. Stoll, Wei Qiu(Nanfang Hospital), Stewart L. Fisher(C4 Therapeutics (United States)), Giovanna Scapin, Keith M. Hamel(AbbVie (United States)), Claudio Catalano(NanoImaging Services), Alexander W. Hird(Paras Hospitals), Dan Eaton, Kenton L. Longenecker(AbbVie (United States)), David Stokoe(Enzo Life Sciences (United States)), Harit U. Vora(C4 Therapeutics (United States)), Qi Sun(AbbVie (United States)), Ping Li(University of Southern California), Manoj K Rathinaswamy(San Francisco VA Medical Center), Rinku Jain(AbbVie (United States)), Christina K. Baumgartner(AbbVie (United States)), Eunice Park(C4 Therapeutics (United States)), Charles W. Hutchins(AbbVie (United States)), Chaohong Sun(AbbVie (United States))
Cited by 9
Related Papers
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
|Cell|2006|1.2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|853
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
|Cancer Cell|2006|584
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
|JNCI Journal of the National Cancer Institute|2005|467